Categories
Commissioner Ex-FDA

Ex-FDA Commissioner Analyzes Johnson & Johnson’s Mega Vaccine Trial – Yahoo Finance

JNJ) plans on enrolling up to 60,000 people in a coronavirus vaccine trial, likely as part of a global development and regulatory approval strategy, ex-FDA Commissioner Scott Gottlieb said Friday on CNBC’s “Squawk Box.”” data-reactid=”19″ type=”text”>Johnson & Johnson (NYSE: JNJ) plans on enrolling up to 60,000 people in a coronavirus vaccine trial, likely as part of a global development and regulatory approval strategy, ex-FDA Commissioner Scott Gottlieb said Friday on CNBC’s “Squawk Box.”

J&J will likely look to oversee large trials in many regions at the same time to make it easier to file for regulatory approval, he said. 

In order to gain regulatory approval from foreign agencies, a vaccine maker needs to conduct studies in that specific region, Gottlieb said.

sign up for our coronavirus newsletter.” data-reactid=”27″ type=”text”>Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.

PFE) are recruiting 30,000 people in the U.S., the ex-FDA commissioner said.” data-reactid=”28″ type=”text”>COVID-19 Timeline Update: Vaccine makers like Pfizer Inc. (NYSE: PFE) are recruiting 30,000 people in the U.S., the ex-FDA commissioner said.

Even at half the size of J&J

Read More